Aktienanalyse zu Grail Inc (GRAL)GRALGrail Inc

Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer. It operates in the Healthcare sector (MEDICAL LABORATORIES industry).

Grail Inc is a good buy right now due to its current price of $132.55, which is significantly lower than analyst price targets, with UBS projecting a potential upside of 32% to $175. The stock has shown strong momentum with a 5-day change of +12.51% and a year-to-date change of +49.15%. However, the main risk is the uncertainty surrounding the FDA approval process for its Galleri test, which is crucial for its profitability.